Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System
LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
Shares of Second Sight Medical Products Inc. soared 104.2% on heavy volume in midday trading Monday, bringing its two-day gain to 728.7%, after the Food and Drug Administration approved the company's ...
Shares of Second Sight Medical Products shot up by nearly tenfold Friday after the Food and Drug Administration cleared for use a visual prosthesis system that the company has redesigned. The company ...
A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...
The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...
Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results